Literature DB >> 28630359

Diagnosis and management of bronchiectasis.

Maeve P Smith1.   

Abstract

KEY POINTS Following a diagnosis of bronchiectasis, it is important to investigate for an underlying cause. Goals of management are to suppress airway infection and inflammation, to improve symptoms and health-related quality of life. There are now validated scoring tools to help assess disease severity, which can help to stratify management. Good evidence supports the use of both exercise training and long-term macrolide therapy in long-term disease management.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28630359      PMCID: PMC5478409          DOI: 10.1503/cmaj.160830

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  79 in total

1.  Inhaled fluticasone in bronchiectasis: a 12 month study.

Authors:  K W Tsang; K C Tan; P L Ho; G C Ooi; J C Ho; J Mak; G L Tipoe; C Ko; C Yan; W K Lam; M Chan-Yeung
Journal:  Thorax       Date:  2005-03       Impact factor: 9.139

Review 2.  The effects of oscillating positive expiratory pressure therapy in adults with stable non-cystic fibrosis bronchiectasis: A systematic review.

Authors:  Annemarie L Lee; Hannah C Williamson; Sarah Lorensini; Lissa M Spencer
Journal:  Chron Respir Dis       Date:  2014-12-17       Impact factor: 2.444

3.  Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.

Authors:  A E O'Donnell; A F Barker; J S Ilowite; R B Fick
Journal:  Chest       Date:  1998-05       Impact factor: 9.410

4.  Use of nebulised saline and nebulised terbutaline as an adjunct to chest physiotherapy.

Authors:  P P Sutton; H G Gemmell; N Innes; J Davidson; F W Smith; J S Legge; J A Friend
Journal:  Thorax       Date:  1988-01       Impact factor: 9.139

5.  Microbiologic follow-up study in adult bronchiectasis.

Authors:  Paul T King; Stephen R Holdsworth; Nicholas J Freezer; Elmer Villanueva; Peter W Holmes
Journal:  Respir Med       Date:  2007-04-30       Impact factor: 3.415

6.  Bronchiectasis in secondary care: a comprehensive profile of a neglected disease.

Authors:  Martin G. Kelly; S. Murphy; J. Stuart Elborn
Journal:  Eur J Intern Med       Date:  2003-12       Impact factor: 4.487

7.  Lung transplantation for non-cystic fibrosis bronchiectasis.

Authors:  Jessica Rademacher; Felix C Ringshausen; Hendrik Suhling; Jan Fuge; Georg Marsch; Gregor Warnecke; Axel Haverich; Tobias Welte; Jens Gottlieb
Journal:  Respir Med       Date:  2016-04-20       Impact factor: 3.415

8.  Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.

Authors:  Charles S Haworth; Juliet E Foweraker; Peter Wilkinson; Robert F Kenyon; Diana Bilton
Journal:  Am J Respir Crit Care Med       Date:  2014-04-15       Impact factor: 21.405

9.  Symptoms of airway reflux predict exacerbations and quality of life in bronchiectasis.

Authors:  P Mandal; A H Morice; J D Chalmers; A T Hill
Journal:  Respir Med       Date:  2013-05-15       Impact factor: 3.415

10.  Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.

Authors:  David J Serisier; Diana Bilton; Anthony De Soyza; Philip J Thompson; John Kolbe; Hugh W Greville; David Cipolla; Paul Bruinenberg; Igor Gonda
Journal:  Thorax       Date:  2013-05-16       Impact factor: 9.139

View more
  4 in total

1.  Daily versus three-times-weekly azithromycin in Chinese patients with non-cystic fibrosis bronchiectasis: protocol for a prospective, open-label and randomised controlled trial.

Authors:  Yanxiong Mao; Lan Chen; Ting He; Jing Li; Aiping Zou; Feng Li; Fei Chen; Bo Fan; Weihao Ni; Wei Xiao; Huimin You; Wenjiang Fu
Journal:  BMJ Open       Date:  2022-07-08       Impact factor: 3.006

2.  Effects of Doxofylline Combined with Ceftazidime on Clinical Efficacy, Drug Safety, and Prognosis in Patients with Chronic Obstructive Pulmonary Disease Complicated with Infection.

Authors:  Ying Wang
Journal:  Med Sci Monit       Date:  2021-08-18

Review 3.  Non-Pharmaceutical Techniques for Obstructive Airway Clearance Focusing on the Role of Oscillating Positive Expiratory Pressure (OPEP): A Narrative Review.

Authors:  Dominic P Coppolo; Judy Schloss; Jason A Suggett; Jolyon P Mitchell
Journal:  Pulm Ther       Date:  2021-12-03

4.  Pneumocystis jirovecii colonization and its association with pulmonary diseases: a multicenter study based on a modified loop-mediated isothermal amplification assay.

Authors:  Ting Xue; Zhuang Ma; Fan Liu; Weiqin Du; Li He; Jinyan Wang; Chunli An
Journal:  BMC Pulm Med       Date:  2020-03-20       Impact factor: 3.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.